Beam Therapeutics to Present New Preclinical Data on Base Editing Programs for Hemoglobinopathies at ASH 2019

Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it will present preclinical data for the companys programs addressing sickle cell disease and beta thalassemia, two blood disorders that lack effective, disease-modifying treatments, at the 61st Annual American Society of Hematology (ASH) Annual Meeting, being held December 7-10, 2019 in Orlando, Fla.